Impact of ABCB1 genetic polymorphism on carbamazepine dose requirement among Southern Indian persons with epilepsy
Author:
Dhivya Elango1, Kesavan Ramasamy1, Pradeep Nair P.2
Affiliation:
1. Department of Pharmacology , 29988 Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) , Puducherry , India 2. Department of Neurology , 29988 Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) , Puducherry , India
Abstract
Abstract
Objectives
Carbamazepine (CBZ) is one of the oldest, yet first line drugs for treating epilepsy. However, there is a large inter-individual difference in requirement of maintenance dose and one third of persons treated with antiepileptic drugs (AEDs) exhibit drug resistance to therapy. One of the proposed mechanisms for the drug resistance was increased expression of efflux transporter P-glycoprotein. The pharmacogenetic studies of drug transporters (ABCB1) done in combination therapies of AEDs were inconclusive. Hence, we have attempted to study the impact of ABCB1 3435C>T genetic polymorphism and CBZ monotherapy in persons with epilepsy (PWE) from South India, which is a genetically distinct population. With this background, this study was aimed to determine the dose of CBZ in ABCB1 3435C>T genotypes and to determine the distribution of ABCB1 3435C>T genotypes (which codes P-glycoprotein) between responders and non-responders to CBZ therapy.
Methods
A cross sectional study was conducted in 200 persons with epilepsy, who were categorised as responders and non-responders according to ILAE (international league against epilepsy) criteria. Eligible participants were enrolled from the epilepsy clinic of the neurology department and five ml of blood was collected. DNA extraction and genotyping were done by phenol-chloroform method and real time polymerase chain reaction (RT-PCR), respectively.
Results
The mean maintenance dose of carbamazepine was statistically significant among different genotypes (p<0.05) of ABCB1 3435C>T (526 vs. 637 mg/day in CC vs. TT genotype). There was no significant association between ABCB1 3435C>T polymorphism (p=0.827) and CBZ resistance in PWE. Duration of disease and age of onset were found to be significant in predicting the response to CBZ therapy.
Conclusions
We report that ABCB1 3435C>T polymorphism is significantly associated with an increase in dose requirement of CBZ in persons with epilepsy from South India.
Publisher
Walter de Gruyter GmbH
Reference30 articles.
1. World Health Organization. Neurological disorders: Public health challenges [internet]. http://www.who.int/mental_health/neurology/neurodiso/en/ [Accessed 19 Nov 2018]. 2. Amudhan, S, Gururaj, G, Satishchandra, P. Epilepsy in India: epidemiology and public health. Ann Indian Acad Neurol 2015;18:263–77. https://doi.org/10.4103/0972-2327.160093. 3. Thorn, CF, Leckband, SG, Kelsoe, J, Leeder, JS, Müller, DJ, Klein, TE, et al.. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genom 2011;21:906–10. https://doi.org/10.1097/fpc.0b013e328348c6f2. 4. Lowenstein, HD. Seizure and epilepsy. In: Kasper, DL, Fausi, AS, Hauser, SL, Lango, DL, Jameson, LJ, Loscalzo, editors. Harrison’s principle of internal medicine. New York: McGraw-Hill; 2015:2542–58 pp. 5. Banerjee, PN, Filippi, D, Allen Hauser, W. The descriptive epidemiology of epilepsy – a review. Epilepsy Res 2009;85:31–45. https://doi.org/10.1016/j.eplepsyres.2009.03.003.
|
|